Abstract: Sterically hindered cyclic amines which are substituted by a photoactivatable acyl group at the basic nitrogen atom can be deacylated by irradiation with UV light. This is advantageous if the basicity of the amines proves troublesome during application. Examples of such photoactivatable acyl groups are phenylglyoxyl, phenylacetyl or naphthylacetyl groups.

Abstract: A compound selected from the group consisting of compounds of the formula (I) ##STR1## The compounds of the formula (I) are useful as light stabilizers, heat stabilizers, and oxidation stabilizers.

Abstract: Compounds of formula I: ##STR1## wherein R is a radical of the formula --OR.sub.3 or --NHR.sub.3, A is a radical of formula II or III: ##STR2## B is a radical of the formula ##STR3## n is the number 1 or 2, R.sub.1 is --H or --Cl, R.sub.2 is --H, halogen, --NO.sub.2, --CN, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, --CF.sub.3, C.sub.2 -C.sub.5 alkoxycarbonyl or --CONH-phenyl, --NHCO-phenyl or phenoxy which is unsubstituted or substituted on the phenyl ring by one or two chlorine atoms or one or two methyl, methoxy or ethoxy groups, R.sub.3 is alkyl containing at least 10 C atoms, R.sub.4 and R.sub.5 are each independently of the other --H, halogen, --NO.sub.2, --CN, --CF.sub.3, C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkoxy, R.sub.6 is --H, --Cl, --Br, --CH.sub.3 or --OCH.sub.3 and X is --H, --Br, --OCH.sub.3, --CN or --NO.sub.

Abstract: The invention relates to the use of ketenethioacetals of the formula ##STR1## in which R.sub.1 represents aryl or heteroaryl, R.sub.2 represents hydrogen, an optionally substituted hydrocarbon radical, heteroaryl, an acyl radical, a group of the formula --S(O).sub.m --R.sub.a, wherein m is 0, 1 or 2 and R.sub.a is an optionally substituted hydrocarbon radical; or optionally functionally modified sulpho, A represents an optionally substituted bivalent aliphatic hydrocarbon radical and n is 0 or 1, and pharmaceutically acceptable salts of such compounds that contains a salt-forming group, for the treatment of liver diseases, respiratory tract diseases and vascular diseases pharmaceutical preparations containing compounds of the formula I and novel compounds of the formula I. The compounds have liver-protecting and immunomodulating properties.

Abstract: Substituted pyrrolidin-2-ones of the formula ##STR1## wherein R.sub.1 represents a phenyl or naphthyl radical that is unsubstituted or substituted by lower alkyl, lower alkloxy, halogen and/or trifluoromethyl, X.sub.1 represents lower alkylidene, X.sub.2 represents methylene, ethylene or oxoethylene and R.sub.2 represents hydrogen, lower alkyl or a radical of the formula ##STR2## wherein X.sub.4 represents lower alkylidene and R.sub.3 represents hydrogen or a phenyl or a phenyl naphthyl radical that is unsubstituted by lower alkyl, lower alkoxy, halogen and/or trifluoromethyl, and their pharmaceutically acceptable salts, have nootropic properties and can be used as nootropic active ingredients in medicaments. They are prepared, for example, by condensing with one another compounds of the formulae ##STR3## wherein Z.sub.1 represents a group of the formula --X.sub.1 --(.dbd.O)--Z.sub.3 (IIa) and Z.sub.2 represents hydrogen, or Z.sub.1 represents hydrogen and Z.sub.2 represents a group of the formula --C(.dbd.

Abstract: N,O-acylates, derived from N-acylated carbamic acids, of desferrioxamine B of the formula ##STR1## in which B represents a carbamoyl radical of the partial formula --CO--NH--Alk--CO--O--R.sub.a.sup.1 (II) in which R.sub.a.sup.1 represents C.sub.1 -C.sub.4 -alkyl or C.sub.2 -C.sub.4 -alkyenyl and Alk represents C.sub.1 -C.sub.7 -alkylene that is optionally substituted by hydroxy, C.sub.1 -C.sub.4 -alkanoyloxy, amino, C.sub.1 -C.sub.4 -alkoxycarbonyl, carbamoyl, phenyl, hydroxyphenyl, methoxyphenyl or by indolyl, and each of the symbols A.sup.1, A.sup.2 and A.sup.3, independently of the others, represents hydrogen, an acyl radical Ac derived from a carboxylic acid, or an above-defined carbamoyl radical of the partial formula II, form strong iron(III) and aluminium complexes in living cells.

Abstract: Alkanediphosphonic acids, in particular heteroarylalkanediphosphonic acids of formula ##STR1## wherein R.sub.1 is a 5-membered heteroaryl radical which may be fused with benzene or cyclohexene nuclei and which contains, as hetero atoms, 2 to 4 N-atoms or 1 or 2 N-atoms as well as 1 O- or S-atom, and which is unsubstituted or C-substituted by lower alkyl, phenyl or phenyl which is substituted by lower alkyl, lower alkoxy and/or halogen, or by lower alkoxy, hydroxy, di-lower alkylamino, lower alkylthio and/or halogen, and/or is N-substituted at a N-atom which is capable of substitution by lower alkyl, lower alkoxy and/or halogen, and R.sub.2 is hydrogen, hydroxy, amino, lower alkylthio or halogen, and salts thereof, have regulatory action on calcium metabolism and can be used as medicaments for the treatment of diseases associated with impairment of calcium metabolism. The compounds are obtained for example by converting, in a compound of formula ##STR2## wherein X.sub.

Abstract: The invention relates to 1,8-dihydroxy-3-methylbenz[b]phenanthridine-7,12-dione and its derivatives of formula I ##STR1## wherein R.sup.1 is hydrogen or the radical of formula II ##STR2## and salts of the compound, wherein R.sup.1 is the radical of formula II. These compounds can be obtained by means of a novel microbiological process and used for the therapeutic treatment of tumors.

Abstract: Hydropyridine derivatives of the formula ##STR1## in which R.sub.1 represents carboxy, lower alkoxycarbonyl, carbamoyl, N-lower alkylcarbamoyl or N,N-di-lower alkylcarbamoyl, R.sub.2 represents hydrogen, an optionally etherified or acylated hydroxy group or an optionally acylated amino group, and R.sub.3 represents a radical of the formula R- (Ia), R-alk.sub.1 - (Ib) or R'=alk.sub.2 - (Ic) in which R represents a benzocycloalkenyl radical having a total of from 8 to 12 ring carbon atoms which is bonded via a saturated carbon atom and which is unsubstituted or is mono- or poly-substituted in the benzo moiety by hydroxy, lower alkoxy, lower alkanoyloxy, halogen, lower alkyl and/or by trifluoromethyl, and/or substituted in the .alpha.

Abstract: A process for the production of aliphatylphosphinic acid derivatives, especially of alkyl dialkoxyalkylphosphinates having the formula I ##STR1## in which R is C.sub.1 -C.sub.4 -alkyl and R' is hydrogen or C.sub.1 -C.sub.4 -alkyl, comprising reacting, in the presence of an acidic catalyst, aqueous phosphonic acid with the corresponding trialkyl orthoester having the formula II:(RO).sub.3 CR' IIin whicih R and R' have their previous significances, the amount of the orthoester of formula II used being equal to, or in excess of the stoichiometric amount of both water and phosphinic acid present in the aqueous phosphinic acid reactant.

Abstract: The present invention relates to electrically conductive polymers obtainable by anodic oxidation of starting polymers consisting of 5-100 mol % of recurring structural units of the formula I and 95-0 mol % of recurring structural units of the formula II ##STR1## in which R.sup.1 and R.sup.4 independently of one another are C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, phenyl or phenoxy, R.sup.2 and R.sup.3 independently of one another are C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halogen, cyano or nitro, R.sup.5 is C.sub.1 -C.sub.18 alkyl, which is unsubstituted or can be substituted by one or two hydroxyl groups, or is phenyl or hydroxyl, m is an integer from 3-11, and n and p independently of one another are integers from 0 to 2.The electrically conductive polymers are colored in the visible region, whereas the electrically insulating starting polymers are not colored in this region.

Abstract: A process for producing glycidylthio ethers of the formula I ##STR1## which process comprises reacting epichlorohydrin with a mercaptan of the formula IIR--SH (II)in which R can be a radical ##STR2## wherein R.sup.1, R.sup.2 and R.sup.3 independently of one another are each C.sub.1 -C.sub.18 -alkyl, and together contain no more than 22 C atoms, and R.sup.2 and R.sup.3 are in addition hydrogen, or wherein R is C.sub.5 -C.sub.6 -cycloalkyl, phenyl or naphthyl unsubstituted or substituted by C.sub.1 -C.sub.4 -alkyl, or is benzyl or furfuryl, or wherein R is C.sub.2 -C.sub.8 -alkylene which is substituted by --SH and which can be interrupted by 1 or 2 ether-O atoms, in an equimolar amount, without organic solvent and in the presence of a base, the reaction being performed by the phase-transfer catalysis process, wherein a phase-transfer catalyst is used, at a temperature of -30.degree. C. to +20.degree. C.

Abstract: Compounds of the formula ##STR1## in which R.sub.1 represents hydrogen or acyl, A represents an optionally N-alkylated .alpha.-amino acid residue which is bonded N-terminally to R.sub.1 and C-terminally to the group --NR.sub.2 --, R.sub.2 represents hydrogen or lower alkyl, R.sub.3 represents hydrogen, lower alkyl, optionally etherified or esterified hydroxy-lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, bicycloalkyl-lower alkyl, tricycloalkyl-lower alkyl, aryl or aryl-lower alkyl, R.sub.4 represents hydroxy or etherified or esterified hydroxy, R.sub.5 represents lower alkyl having 2 or more carbon atoms, optionally etherified or esterified hydroxy-lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, bicycloalkyl, bicycloalkyl-lower alkyl, tricycloalkyl, tricycloalkyl-lower alkyl, aryl, aryl-lower alkyl, optionally substituted carbamoyl, optionally substituted amino, optionally substituted hydroxy or optionally substituted mercapto and R.sub.

Abstract: The invention relates to a novel process for the manufacture of (3R,1'R)-4-acyloxy-3-(1'-hydroxyethyl)-2-azetidinones of formula ##STR1## in which R.sup.1 represents lower alkyl or aryl, by enantioselective reduction of the carbonyl group in a suitable .alpha.-acylaminomethyl-acetoacetic acid ester, cyclization of the resulting .alpha.-acylaminomethyl-.beta.-hydroxybutyric acid ester to a 5,6-dihydro-1,3,4H-oxazine with inversion of the carbon atom carrying the hydroxy group, equilibration to form the preferred trans-substituted dihydrooxazine, recleaving to form the configuratively uniform .alpha.-aminomethyl-.beta.-hydroxybutyric acid, ring-closure to form the .beta.-lactam and oxidative acylation at C(4) of the .beta.-lactam. Compounds of formula I can be used as starting materials for the manufacture of .beta.-lactam antibiotics. The invention relates also to novel intermediates.

Abstract: An amine hardener comprising diethyltoluenediamine or t-butyl-meta-toluenediamine and 4,4'-methylene orthoethylaniline and curable polyurethane casting systems comprising said hardener and an isocyanate resin.

Abstract: Moulding compositions comprising(a) a melamine/formaldehyde resin, a melamine/phenol/formaldehyde resin or a mixture of said resins,(b) organic and/or inorganic fillters,(c) a lubricant, and(d) 0.1 to 2% by weight, based on on the total composition, of 3-chloro-1,2-propanediol as latent hardener,are suitable for the production of mouldings by injection moulding. The latent hardener employed permits extremely short cycle times coupled with long residence times at the cylinder temperature of the injection moulding machine. The moulding compositions are distinguished at the same time by very good flow properties.

Abstract: A one step process for the preparation of bis(2,2,6,6-tetramethyl-4-piperidyl)amine by reacting 2,2,6,6-tetramethyl-4-piperidone or 2,2,6,6-tetramethyl-4-piperidone x H.sub.2 O with ammonia and hydrogen in the presence of a hydrogenation catalyst, characterized in that the molar ratio of 2,2,6,6-tetramethyl-4-piperidone versus ammonia is between 1:0.4 and 1:0.8.

Abstract: An oil recovery process comprising contacting an oil deposit with a blend of chemicals containing a fluorochemical of the formula[(R.sub.f).sub.n (R').sub.p ].sub.m Z (I)wherein each R.sub.f is independently a perfluoroaliphatic or omega-hydroperfluoroaliphatic group each of which is optionally interrupted by carbonyl, carboxy, carbonylamino, oxygen, sulfur, sulfinyl, or sulfonyl; n is 1-3 and p is 0 or 1 provided what when p is 0, n is 1; m is 1-5000; each R' is independently an organic linking group between R.sub.f and Z having a valency of n+1; and Z is a hydrocarbyl containing residue of valency m.

Abstract: A functional fluid comprising:(a) a base fluid selected from one or more of (i) a phosphate fluid and (ii) a carboxylic acid ester; and(b) as hydrolytic stabilizer, at least one compound having the formula I:A--NHC(.dbd.X)NHZ (I),in whichA is hydrogen, C.sub.1 -C.sub.23 alkyl, C.sub.3 -C.sub.18 alkenyl, C.sub.6 -C.sub.10 aryl, C.sub.7 -C.sub.13 alkaryl, C.sub.7 -C.sub.13 aralkyl or C.sub.5 -C.sub.12 cycloalkyl;X is oxygen, sulphur or NH; andZ is H, NH.sub.2 or --N.dbd.CR.sub.1 R.sub.2 in which R.sub.1 and R.sub.2, independently, have any of the meanings assigned to A, or R.sub.2 is H, or R.sub.1 and R.sub.2, together with the carbon atom to which they are each attached, may form a C.sub.5 -C.sub.12 ring.

Abstract: Novel topically administrable pharamceutical composition containing, as active ingredient, from approximately 0.1 to approximately 10% by weight of a non-steroidal, anti-inflammatorially active compound having at least one acidic group, from approximately 10 to approximately 50% by weight of a water-soluble, volatile lower alkanol having from 2 up to and including 4 carbon atoms, from approximately 3 to approximately 15% by weight of an optionally self-emulsifying lipid or a mixture of lipids, from approximately 0.5 to approximately 2% by weight of a gel structure former, from approximately 1 to approximately 20% by weight of a co-solvent, from approximately 40 to approximately 80% by weight of water, optionally from approximately 0.5 to approximately 5% by weight of an emulsifier if the lipid phase is not self-emulsifying and, if desired, non-essential constituents.